ABT-267 Property

Melting point:

>177°C (dec.)

Boiling point:

1065.6±65.0 °C(Predicted)

Density 

1.223±0.06 g/cm3(Predicted)

storage temp. 

-20°C Freezer, Under inert atmosphere

solubility 

DMSO (Slightly), Methanol (Slightly)

pka

10.92±0.46(Predicted)

form 

Solid

color 

Off-White to Pale Beige

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H315Causes skin irritation

H319Causes serious eye irritation

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P332+P313IF SKIN irritation occurs: Get medical advice/attention.

P337+P313IF eye irritation persists: Get medical advice/attention.

ABT-267 Chemical Properties,Usage,Production

Description

Ombitasvir hydrate is a NS5A non-nucleoside polymerase inhibitor which is approved as part of a four drug combination for the treatment of adults with genotype 1 hepatitis C virus infection including those with compensated cirrhosis. The four drug combination treatment consists of ombitasvir, paritaprevir (XXVII), ritonavir, and dasabuvir (X). This combination treatment is marketed as Viekira Pak and was developed by Abbvie as an all oral treatment that eliminates the need for pegylated interferon- a injections.

Uses

Ombitasvir is a pharmaceutical drug that is used in the treatment of hepatitis C virus in patients with HCV genotype 1 infection. It inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly, and secretion.

Definition

ChEBI: A dipeptide derivative which is used which is in combination with dasabuvir sodium hydrate, paritaprevir and ritonavir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.

Clinical Use

Treatment of chronic hepatitis C infection

Synthesis

Alkylation of 1-(4-nitrophenyl)ethanone (209) with 2-bromo-1-(4-nitrophenyl)ethanone (208) in the presence of zinc chloride produced diketone 210 in 61% yield. Asymmetric reduction of the diketone using N,N-diethylaniline borane with (S)-(-)-a,a-diphenyl-2-pyrrolidinemethanol (211) and trimethoxyborate gave diol 212 in 61% yield and 99.3% ee. The diol was then treated with methanesulfonic anhydride to generate the corresponding bis-mesylate which was reacted with 4-tert-butylaniline to give pyrrolidine 213 in 51% yield over the two steps. Hydrogenolysis of the nitro groups was accomplished using Raney nickel catalyst to give bis-aniline 214. Separately, (L)-valine (216) was reacted with methyl chloroformate to give the corresponding methyl carbamate in 90% yield which was coupled to L-proline benzyl ester in the presence of EDC and HOBt to give the corresponding dipeptide in 90% yield. Hydrogenolysis of the benzyl ester group of the protected dipeptide using Pd/alumina catalyst produced dipeptide acid 215. Aniline 214 was treated with two equivalents of acid 215 in the presence of 1-propanephosphonic acid cyclic anhydride (T3P). The crude product was recrystallized from ethanol and heptane to give ombitasvir hydrate (XXV). No yields were provided to the final steps of this synthesis.

Enzyme inhibitor

This N-phenylpyrrolidine-based, pan-genotypic HCV NS5A protease inhibitor (FW = 893.14 g/mol), also named ABT-267, targets Nonstructural protein 5A (NS5A), a zinc-binding and proline-rich hydrophilic phosphoprotein that plays a key role in Hepatitis C virus RNA replication.Ombitasvir exhibits low-picomolar EC50 values against Hepatitis C virus, with superior pharmacokinetics. Although ombitasvir shows a low barrier to resistance, when given as monotherapy, co-administration with other antivirals enhances its barrier to resistance. Indeed, a 12-week, Phase- 3 study demonstrated that a multi-targeted regimen consisting of ombitasvir, dasabuvir and ribavirin is highly effective and showed a low rate of treatment discontinuation.

Drug interactions

Potentially hazardous interactions with other drugs See also ritonavir interactions. Ombitasvir:
Antibacterials: concentration possibly reduced by rifampicin - avoid.
Antidepressants: concentration possibly reduced by St John’s wort - avoid.
Antiepileptics: concentration reduced by carbamazepine - avoid, concentration possibly reduced by fosphenytoin, phenobarbital, phenytoin and primidone - avoid.
Diuretics: concentration of furosemide reduced (reduce furosemide dose).
Immunosuppressants: increases concentration of ciclosporin (reduce ciclosporin dose by a fifth); everolimus (avoid); sirolimus and tacrolimus (reduce dose and use only if benefit outweighs risk - see SPC).
Oestrogens: avoid with ethinyloestradiol.
Statins: avoid with atorvastatin and simvastatin. Paritaprevir:
Antibacterials: avoid with clarithromycin; concentration possibly reduced by rifampicin - avoid.
Antidepressants: concentration possibly reduced by St John’s wort - avoid.
Antiepileptics: concentration reduced by carbamazepine - avoid; possibly reduced by fosphenytoin, phenobarbital, phenytoin and primidone - avoid.
Antifungals: concentration of both drugs increased with ketoconazole and possibly itraconazole and posaconazole - avoid.
Antivirals: concentration increased by atazanavir; concentration increased by darunavir and concentration of darunavir decreased; avoid with efavirenz, etravirine, indinavir, nevirapine, saquinavir and tipranavir; concentration increased by lopinavir - avoid.
Diuretics: concentration of furosemide increased (reduce furosemide dose).
Immunosuppressants: increases concentration of ciclosporin (reduce ciclosporin dose by a fifth); everolimus (avoid); sirolimus and tacrolimus (reduce
Antidepressants: concentration possibly reduced by St John’s wort - avoid.
Antiepileptics: concentration reduced by carbamazepine - avoid; possibly reduced by fosphenytoin, phenobarbital, phenytoin and primidone - avoid.
Antifungals: concentration of both drugs increased with ketoconazole and possibly itraconazole and posaconazole - avoid.
Antivirals: concentration increased by atazanavir; concentration increased by darunavir and concentration of darunavir decreased; avoid with efavirenz, etravirine, indinavir, nevirapine, saquinavir and tipranavir; concentration increased by lopinavir - avoid.
Diuretics: concentration of furosemide increased (reduce furosemide dose).
Immunosuppressants: increases concentration of ciclosporin (reduce ciclosporin dose by a fifth); everolimus (avoid); sirolimus and tacrolimus (reduce

Metabolism

Ombitasvir is metabolised via amide hydrolysis followed by oxidative metabolism. A total of 13 metabolites were identified in human plasma. These metabolites are not expected to have antiviral activity or off-target pharmacologic activity.
Paritaprevir is metabolised mainly by CYP3A4 and to a lesser extent CYP3A5. Following administration of a single 200 mg / 100 mg oral dose of 14C paritaprevir / ritonavir to humans, the parent drug was the major circulating component, accounting for approximately 90% of the plasma radioactivity.
At least 5 minor metabolites of paritaprevir have been identified in circulation that accounted for approximately 10% of plasma radioactivity.
These metabolites are not expected to have antiviral activity. Ritonavir is extensively metabolised in the liver mainly by cytochrome P450 isoenzymes CYP3A4 and to a lesser extent by CYP2D6. Five metabolites have been identified and the major metabolite has antiviral activity, but concentrations in plasma are low. About 86% of a dose is eliminated through the faeces (both as unchanged drug and as metabolites) and about 11% is excreted in the urine.